Stock Events

Stock Events

Tvardi Therapeutics 

€0
0
+€0+0% Today

Statistics

Day High
-
Day Low
-
52W High
-
52W Low
-
Volume
-
Avg. Volume
-
Mkt Cap
0
P/E Ratio
-
Dividend Yield
-
Dividend
-

People Also Follow

This list is based on the watchlists of people on Stock Events who follow 69C.MU. It's not an investment recommendation.

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Vertex Pharmaceuticals
VRTX
Mkt Cap111.43B
Vertex Pharmaceuticals is involved in creating treatments for pain management, directly competing with Cara Therapeutics' focus on novel pain therapies.
Teva- Pharmaceutical Industries
TEVA
Mkt Cap35.03B
Teva Pharmaceutical Industries has a broad portfolio that includes pain management solutions, making it a competitor in the same therapeutic area as Cara Therapeutics.
Johnson & Johnson
JNJ
Mkt Cap585.7B
Johnson & Johnson, through its pharmaceutical segment, develops drugs for various conditions including pain, competing with Cara Therapeutics' pain management products.
Abbvie
ABBV
Mkt Cap369.39B
AbbVie has a strong presence in the pain management market with its portfolio of analgesics, competing with Cara Therapeutics.
Pfizer
PFE
Mkt Cap161.09B
Pfizer has a diverse drug portfolio that includes pain management medications, positioning it as a competitor to Cara Therapeutics.
Novartis
NVS
Mkt Cap297.32B
Novartis AG offers a range of pain management solutions, making it a direct competitor in the therapeutic area that Cara Therapeutics targets.
Merck
MRK
Mkt Cap298.84B
Merck & Co., Inc. develops medications for various therapeutic areas, including pain, competing with Cara Therapeutics' focus.
Gilead Sciences
GILD
Mkt Cap173.41B
Gilead Sciences, though primarily known for antiviral drugs, has ventured into other therapeutic areas, including pain management, competing with Cara Therapeutics.
Alkermes
ALKS
Mkt Cap5.81B
Alkermes plc works on central nervous system (CNS) disorders, including treatments for pain, positioning it as a competitor to Cara Therapeutics.

About

Tvardi Therapeutics is a clinical-stage biopharmaceutical company focused on developing novel, oral small molecule therapies targeting STAT3 to treat fibrosis-driven diseases with significant unmet need. Their lead candidate, TTI-101, is currently in Phase 2 clinical trials for idiopathic pulmonary fibrosis (IPF) and hepatocellular carcinoma (HCC).
Show more...
CEO
Dr. Imran Alibhai Ph.D.
Employees
17
Country
United States
ISIN
US1407553072

Listings

XNAS
US
TVRD
LSE
GB
0HTC.LSE
MU
DE
69C.MU
F
DE
69C.F

0 Comments

Share your thoughts

FAQ

What is Tvardi Therapeutics stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on exchange Tvardi Therapeutics stocks are traded under the ticker 69C.MU.
How many employees does Tvardi Therapeutics have?▼
As of April 12, 2026, the company has 17 employees.
In which sector is Tvardi Therapeutics located?▼
Tvardi Therapeutics operates in the Health & Wellness sector.
When did Tvardi Therapeutics complete a stock split?▼
Tvardi Therapeutics has not had any recent stock splits.
Where is Tvardi Therapeutics headquartered?▼
Tvardi Therapeutics is headquartered in Sugar Land, United States.